Literature DB >> 26045838

Association of complement factor H gene polymorphisms with age-related macular egeneration susceptibility.

Xiao-Feng Hao1, Li-Ke Xie1, You-Zhi Tang1, Wan-Kun Xie1, Zhi-Fang Zhang1, Yi-Xin Qi1, Wen-Zheng Xiao1, Jing Zhang1.   

Abstract

OBJECTIVE: This study was aimed to confirm whether I62V and Y402H polymorphisms of complement factor H (CFH) were risk factors for age-related macular degeneration (AMD).
METHOD: 109 AMD patients and 165 AMD-free controls were enrolled in the study. The I62V and Y402H polymorphisms were analyzed by polymerase chain reaction-restriction fragment length of polymorphism (PCR-RFLP). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by the X2 test to assess the relationship of I62V and Y402H polymorphisms with AMD risk. Analysis of haplotype and stratification by age and smoking status was conducted as well.
RESULTS: AA genotype and A allele of I62V polymorphism was significantly associated with increased risk for AMD (OR=3.75, 95% CI=1.70-8.30; OR=1.64, 95% CI=1.14-2.36). For Y402H polymorphism, CT genotype showed strong effects on the occurrence of AMD (OR=2.10, 95% CI=1.04-4.27). Moreover, C allele was also a risk factor for AMD (OR=1.95, 95% CI=1.02-3.72). The haplotypes analysis suggested that the risk for AT haplotype carriers was high, compared with GT haplotype (OR=3.91, 95% CI=2.58-5.94). In addition, we found that smoking status could affect the genotype distribution of Y402H polymorphism (P<0.05).
CONCLUSIONS: Our results revealed that CFH polymorphisms I62V and Y402H might be associated with the susceptibility to AMD in Chinese population.

Entities:  

Keywords:  AMD; CFH; polymorphism; susceptibility

Mesh:

Substances:

Year:  2015        PMID: 26045838      PMCID: PMC4440147     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

Review 1.  Epidemiology of age-related maculopathy: a review.

Authors:  Redmer van Leeuwen; Caroline C W Klaver; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients.

Authors:  Ling-Ing Lau; Shih-Jen Chen; Ching-Yu Cheng; May-Yung Yen; Fenq-Lih Lee; Ming-Wei Lin; Wen-Ming Hsu; Yau-Huei Wei
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

3.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; K L Linton
Journal:  Ophthalmology       Date:  1992-06       Impact factor: 12.079

4.  The prevalence of age-related maculopathy: the visual impairment project.

Authors:  M R VanNewkirk; M B Nanjan; J J Wang; P Mitchell; H R Taylor; C A McCarty
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079

5.  No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese.

Authors:  Norimoto Gotoh; Ryo Yamada; Hitomi Hiratani; Victor Renault; Sachiko Kuroiwa; Marion Monet; Sachiko Toyoda; Shohei Chida; Michiko Mandai; Atsushi Otani; Nagahisa Yoshimura; Fumihiko Matsuda
Journal:  Hum Genet       Date:  2006-05-19       Impact factor: 4.132

6.  Complement factor H polymorphisms, renal phenotypes and age-related macular degeneration: the Blue Mountains Eye Study.

Authors:  C Xing; T A Sivakumaran; J J Wang; E Rochtchina; T Joshi; W Smith; P Mitchell; S K Iyengar
Journal:  Genes Immun       Date:  2008-03-13       Impact factor: 2.676

7.  Complement factor H variant increases the risk for early age-related macular degeneration.

Authors:  Jane-Ming Lin; Yi-Yu Tsai; Lei Wan; Hui-Ju Lin; Yushin Tsai; Cheng-Chun Lee; Chang-Hai Tsai; Fuu-Jen Tsai; Sung-Huei Tseng
Journal:  Retina       Date:  2008 Nov-Dec       Impact factor: 4.256

Review 8.  The epidemiology of age-related macular degeneration.

Authors:  Ronald Klein; Tunde Peto; Alan Bird; Mylan R Vannewkirk
Journal:  Am J Ophthalmol       Date:  2004-03       Impact factor: 5.258

9.  Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy.

Authors:  Kelvin Y Lee; Eranga N Vithana; Ranjana Mathur; Victor H Yong; Ian Y Yeo; Anbupalam Thalamuthu; Mun-Wai Lee; Adrian H Koh; Marcus C Lim; Alicia C How; Doric W Wong; Tin Aung
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06       Impact factor: 4.799

10.  Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans.

Authors:  Na Rae Kim; Ju Hee Kang; Oh Woong Kwon; Seok Joon Lee; Jung Hyub Oh; Hee Seung Chin
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01-25       Impact factor: 4.799

View more
  3 in total

1.  Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).

Authors:  Nur Afiqah Mohamad; Vasudevan Ramachandran; Patimah Ismail; Hazlita Mohd Isa; Yoke Mun Chan; Nor Fariza Ngah; Norshakimah Md Bakri; Siew Mooi Ching; Fan Kee Hoo; Wan Aliaa Wan Sulaiman; Liyana Najwa Inche Mat; Mohd Hazmi Mohamed
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

2.  Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population.

Authors:  Fernando Cruz-Gonzalez; Lucia Cabrillo-Estevez; Vanesa Rivero-Gutierrez; Ana Sanchez-Jara; Lourdes De Juan-Marcos; Rogelio Gonzalez-Sarmiento
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

3.  Methodological Appraisal of Literature Concerning the Analysis of Genetic Variants or Protein Levels of Complement Components on Susceptibility to Infection by Trypanosomatids: A Systematic Review.

Authors:  Thais Cristina Tirado; Larine Lowry Moura; Patrícia Shigunov; Fabiano Borges Figueiredo
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.